Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q37307819)
Watch
English
Bevacizumab in the treatment of HER2-negative breast cancer
scientific article published on December 2008
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Q5412157
PMCID
2727886
retrieved
19 August 2017
review article
1 reference
stated in
Q5412157
title
Bevacizumab in the treatment of HER2-negative breast cancer
(English)
1 reference
stated in
Q5412157
PMCID
2727886
retrieved
19 August 2017
main subject
bevacizumab
1 reference
based on heuristic
inferred from title
author name string
Vito Lorusso
series ordinal
1
1 reference
stated in
Q5412157
PMCID
2727886
retrieved
19 August 2017
publication date
1 December 2008
1 reference
stated in
Q5412157
PMCID
2727886
retrieved
19 August 2017
published in
Biologics: Targets and Therapy
1 reference
stated in
Q5412157
PMCID
2727886
retrieved
19 August 2017
volume
2
1 reference
stated in
Q5412157
PMCID
2727886
retrieved
19 August 2017
page(s)
813-821
1 reference
stated in
Q5412157
PMCID
2727886
retrieved
19 August 2017
issue
4
1 reference
stated in
Q5412157
PMCID
2727886
retrieved
19 August 2017
cites work
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727886
retrieved
6 September 2017
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727886
retrieved
6 September 2017
Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727886
retrieved
6 September 2017
Bevacizumab--current status and future directions
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727886
retrieved
6 September 2017
Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727886
retrieved
6 September 2017
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727886
retrieved
6 September 2017
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727886
retrieved
6 September 2017
The anti-angiogenic basis of metronomic chemotherapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727886
retrieved
6 September 2017
A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727886
retrieved
6 September 2017
Therapies directed at vascular endothelial growth factor
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727886
retrieved
6 September 2017
Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727886
retrieved
6 September 2017
The biology of vascular endothelial growth factor
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727886
retrieved
6 September 2017
Antitumor activity of capecitabine and bevacizumab combination in a human estrogen receptor-negative breast adenocarcinoma xenograft model
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727886
retrieved
14 September 2017
Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727886
retrieved
14 September 2017
Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727886
retrieved
14 September 2017
Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human p
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727886
retrieved
26 June 2018
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727886
retrieved
2 September 2018
Advances in adjuvant therapy for breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727886
retrieved
2 September 2018
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727886
retrieved
2 September 2018
Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and docetaxel in a human prostate cancer PC-3 model
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727886
retrieved
2 September 2018
Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727886
retrieved
2 September 2018
The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727886
retrieved
2 September 2018
Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470).
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727886
retrieved
2 September 2018
Five years of clinical experience with metronomic chemotherapy: achievements and perspectives
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/19707460
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
RiBBON 1 and RiBBON 2: phase III trials of bevacizumab with standard chemotherapy for metastatic breast cancer
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/19707460
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/19707460
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/19707460
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/19707460
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/19707460
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/19707460
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.2147/BTT.S3515
1 reference
stated in
Q5412157
PMCID
2727886
retrieved
19 August 2017
PMCID
2727886
1 reference
stated in
Q5412157
PMCID
2727886
retrieved
19 August 2017
PubMed ID
19707460
1 reference
stated in
Q5412157
PMCID
2727886
retrieved
19 August 2017
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
